ROLE OF 11 β-HYDROXYSTEROID DEHYDROGENASE INHIBITORS IN METABOLIC SYNDROME AND ITS EXPANSION IN OTHER THERAPEUTIC OPTIONS

1. Adcock IM, Cosio B, Tsaprouni L, Barnes
PJ, Ito K: Redox Regulation of Histone
Deacetylases and Glucocorticoid-Mediated
Inhibition of the Inflammatory Response.
Antioxidant & Redox Signaling 2005; 7(1-2):
144-152.
2. Adcock IM, Ito K, Barnes PJ
Glucocorticoids: Effects on Gene
Transcription. Proc. Am. Thorac.Soc. 2004;
1(3): 247-254.
3. Barnes PJ, Adcock I: Anti-inflammatory
actions of steroids: molecular mechanisms.
Trends. Pharmacol. Sci. 1993; 14(12): 436-
441.
4. Nonogaki K, Iguchi A: Role of central
neural mechanisms in the regulation of
hepatic glucose metabolism. Life Sci. 1997;
60(11): 797-807.
5. Agarwal AK, Monder C, Eckstein B, White
PC: Cloning and expression of rat cDNA
encoding corticosteroid 11 betadehydrogenase.
J. Biol. Chem. 1989;
264:18939–18943.
6. Albiston AL, Obeyesekere VR, Smith RE,
Krozowski ZS: Cloning and tissue
distribution of the human 11 betahydroxysteroid
dehydrogenase type 2
enzyme. Mol. Cell. Endocrinol. 1994; 105:
R11–R17.
7. Walker BR, JR Seckl: 11betahydroxysteroid
dehydrogenase type 1 as a
novel therapeutic target in metabolic and
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
90
neurodegenerative disease. Expert Opin.
Ther. Targets 2003; 7: 771–783.
8. Masuzaki H, Flier JS. Tissue-specific
glucocorticoid reactivating enzyme, 11
beta-hydroxysteroid dehydrogenase type 1
(11 beta- HSD1)–a promising drug target for
the treatment of metabolic syndrome. Curr.
Drug Targets Immune Endocr. Metabol.
Disord. 2003; 3: 255–262.
9. Stewart PM: Tissue-specific Cushing’s
syndrome, 11betahydroxysteroid
dehydrogenases and the redefinition of
corticosteroid hormone action. Eur. J.
Endocrinol. 2003; 149: 163–168.
10. Stewart PM: Tissue-specific Cushing’s
syndrome uncovers a new target in treating
the metabolic syndrome- 11β-
hydroxysteroid dehydrogenase type 1. Clin.
Med. 2005; 5(2): 142-146.
11. Bahr V, Pfeiffer AF, Diederich S: The
metabolic syndrome x and peripheral
cortisol synthesis. Exp. Clin. Endocrinol.
Diabetes 2002; 110(7): 313-318.
12. Thieringer R, Hermanowski-Vosatka A:
Inhibition of 11β-HSD1 as a novel treatment
for the metabolic syndrome: do
glucocorticoids play a role?. Exp. Rev.
Cardiovasc.Ther. 2005; 3(5): 911-924.
13. Tomlinson JW, Walker EA, Bujalska IJ,
Draper N, Lavery GG, Cooper MS, et al: 11β-
Hydroxysteroid Dehydrogenase Type 1: A
Tissue-Specific Regulator of Glucocorticoid
Response. Endocr. Rev. 2004; 25(5): 831-
866.
14. Xiangdong Su, Nigel Vicker, Mark P:
Thomas, Fabienne Pradaux-Caggiano,
Heather Halem, Michael D. Culler, and Barry
V. L. Potter: Discovery of Adamantyl
Heterocyclic Ketones as Potent 11β-
Hydroxysteroid Dehydrogenase Type 1
Inhibitors. Chem. Med. Chem. 2011; 6: 1439
– 1451.
15. Walker BR, Connacher AA, Lindsay RM,
Webb DJ, Edwards CR: Carbenoxolone
increases hepatic insulin sensitivity in man:
a novel role for 11-oxosteroid reductase in
enhancing glucocorticoid receptor
activation. J. Clin. Endocrinol. Metab. 1995;
80: 3155–3159.
16. Seckl JR, Walker BR: 11beta
Hydroxysteroid dehydrogenase type 1—a
tissue-specific amplifier of glucocorticoid
action. Endocrinology 2001; 142: 1371–
1376.
17. Walker BR, Connacher AA, Lindsay RM,
Webb DJ, Edwards CR: Carbenoxolone
18. increases hepatic insulin sensitivity in
man: a novel role for 11-oxosteroid
reductase
19. in enhancing glucocorticoid receptor
activation. J. Clin. Endocrinol. Metab. 1995;
80: 3155–3159.
20. Jamieson PM, Walker BR, Chapman KE,
Andrew R, Rossiter S, Seckl JR: 11 betahydroxysteroid
dehydrogenase type 1 is a
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
91
predominant 11 beta-reductase in the
intact perfused rat liver. J. Endocrinol. 2000;
165(3): 685-692.
21. Low SC, Chapman K.E, Edwards CR, Seckl
JR: 'Liver-type' 11β-hydroxysteroid
dehydrogenase cDNA encodes reductase
but not dehydrogenase activity in intact
mammalian COS-7 cells. J. Mol. Endocrinol.
1994; 13(2): 167-174.
22. Jamieson PM, Chapman KE, Edwards CR,
Seckl JR: 11 beta-hydroxysteroid
dehydrogenase is an exclusive 11 betareductase
in primary cultures of rat
hepatocytes: effect of physicochemical and
hormonal manipulations. Endocrinology
1995; 136(11): 4754-4761.
23. Voice MW, Seckl JR, Edwards CR,
Chapman KE: 11b-Hydroxysteroid
dehydrogenase type 1 expression in 2S
FAZA hepatoma cells is hormonally
regulated: a model system for the study of
hepatic glucocorticoid metabolism.
Biochem. J. 1996; 317(Pt 2): 621-625.
24. Kotelevtsev Y, Holmes MC, Burchell A,
Houston PM, Schmoll D , Jamieson P, et al:
11β-Hydroxysteroid dehydrogenase type 1
knockout mice show attenuated
glucocorticoid-inducible responses and
resist hyperglycemia on obesity or stress.
Proc. Natl. Acad. Sci. USA. 1997; 94(26):
14924-14929.
25. Hewitt KN, Walker EA, Stewart PM:
Hexose-6-phosphate dehydrogenase and
redox control of 11 beta hydroxysteroid
dehydrogenase type 1 activity.
Endocrinology 2005;146: 2539–2543.
26. Banhegyi G, Benedetti A, Fulceri R,
Senesi S: Cooperativity between 11betahydroxysteroid
dehydrogenase type 1 and
hexose-6-phosphate dehydrogenase in the
lumen of the endoplasmic reticulum. J. Biol.
Chem. 2004; 279: 27017–27021.
27. Atanasov AG, Nashev LG, Schweizer
RAS, Frick C, Odermatt A: Hexose-6-
phosphate dehydrogenase determines the
reaction direction of 11betahydroxysteroid
Dehydrogenase type 1 as an oxoreductase.
FEBS Lett. 2004; 571(1-3): 129–133.
28. Thieringer R, Le Grand CB, Carbin L, Cai
TQ, Wong B, Wright SD, et al.: 11beta-
Hydroxysteroid dehydrogenase type 1 is
induced in human monocytes upon
differentiation to macrophages. J. Immunol.
2001; 167: 30–35.
29. Hammani MM, Siiteri PK: Regulation of
11 beta hydroxysteroid dehydrogenase
activity in human skin fibroblasts: enzymatic
modulation of glucocorticoid action. J. Clin.
Endocrinol. Metab. 1991; 73: 326–334.
30. Moore JS, Monson JP, Kaltsas G,
Putignano P, Wood PJ, Sheppard MC, et al:
Modulation of 11 beta hydroxysteroid
dehydrogenase isozymes by growth
hormone and insulin-like growth factor: in
vivo and in vitro studies. J. Clin. Endocrinol.
Metab. 1999; 84(11): 4172– 4177.
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
92
31. Trainer PJ, Drake WM, Perry LA, Taylor
NF, Besser GM, Monson JP: Modulation of
cortisol metabolism by the growth hormone
receptor antagonist pegvisomant in
patients with acromegaly. J. Clin.
Endocrinol. Metab. 2001; 86: 2989–2992.
32. Berger J, Tanen M, Elbrecht A,
Hermanowski-Vosatka A, Moller DE, Wright
SD. Peroxisome proliferatoractivated
receptor-ligands inhibit adipocyte 11betahydroxysteroid
dehydrogenase type 1
expression and activity. J. Biol. Chem. 2001;
276: 12629–12635.
33. Hermanowski-Vosatka A, Gerhold D,
Mundt SS, Loving VA, Lu M, Y Chen, et al:
PPARalpha agonists reduce 11betahydroxysteroid
dehydrogenase type 1 in the
liver. Biochem. Biophy. Res. Commun. 2000;
279(2): 330–336.
34. Hermanowski-Vosatka A, David G,
Steven SM, Vilert AL, Meiqing L, Yuli C, et al:
PPAR alpha agonists reduce 11betahydroxysteroid
dehydrogenase type 1 in the
liver. Biochem. Biophy. Res. Commun. 2002;
279(2): 330–336.
35. Morton NM, Ramage L, Seckl JR: Downregulation
of adipose 11 beta
hydroxysteroid dehydrogenase type 1 by
high-fat feeding in mice: a potential
adaptive mechanism counteracting
metabolic disease. Endocrinology 2004;
145: 2707–2712.
36. Bujalska IJ, Walker EA, Hewison M,
Stewart PM: A Switch in Dehydrogenase to
Reductase Activity of 11β-Hydroxysteroid
Dehydrogenase Type 1 upon Differentiation
of Human Omental Adipose Stromal Cells.
J.Clin.Endocrinol. Metab. 2002; 87(3): 1205-
1210.
37. 35.Bujalska IJ, Walker EA, Tomlinson JW,
Hewison M, Stewart PM: 11β-
hydroxysteroid dehydrogenase type 1 in
differentiating omental human
preadipocytes: from de-activation to
generation of cortisol. Endocr. Res. 2002;
28(4): 449-461.
38. Tomlinson JW, Sinha B, Bujalska I,
Hewison M, Stewart PM: Expression of
11β-Hydroxysteroid Dehydrogenase Type 1
in Adipose Tissue Is Not Increased in Human
Obesity. J. Clin. Endocrinol. Metab. 2002;
87(12): 5630-5635.
39. Tomlinson JW, Moore J, Cooper MS,
Bujalska I, Shahmanesh M, Burt C, et al:
Regulation of Expression of 11β-
Hydroxysteroid Dehydrogenase Type 1 in
Adipose Tissue: Tissue-Specific Induction by
Cytokines. Endocrinology 2001; 142(5):
1982-1989.
40. Franks PW, Knowler WC, Nair S, Koska J,
Lee YH, Lindsay RS, et al: Interaction
between an 11betaHSD1 gene variant and
birth era modifies the risk of hypertension
in Pima Indians. Hypertension 2004; 44:
681–688.
41. Caramelli E, Strippoli P, Giacomi T DI,
Catleen T, Paolo C, Renato P: Lack of
mutations of type 1 11[beta]-
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
93
hydroxysteroid dehydrogenase gene in
patients with abdominal obesity. Endocr.
Res. 2001; 27(1-2): 47–61.
42. Draper N, Echwald SM, Lavery GG,
Walker EA, Fraser R, Davies E, et al:
Association studies between microsatellite
markers within the gene encoding human
11betahydroxysteroid dehydrogenase type
1 and body mass index, waist to hip ratio,
and glucocorticoid metabolism. J. Clin.
Endocrinol. Metab. 2002; 87(11): 4984–
4990.
43. Gelernter-Yaniv L, Feng N, Sebring NG,
Hochberg Z, Yanovski JA: Associations
between polymorphism in the 11 beta
hydroxysteroid dehydrogenase type I gene
and body composition. Int. J. Obes. Relat.
Metab. Disord. 2003; 27: 983–986.
44. Schadt EE, Lamb J, Yang X, Zhu J,
Edwards S, Guhathakurta D, et al: An
integrative genomics approach to infer
causal associations between gene
expression and disease. Nat. Genet. 2005;
37: 710–717.
45. Otieno CJ, Bastiaansen J, Ramos AM,
Rothschild MF: Mapping and association
studies of diabetes related genes in the pig.
Anim. Genet.2005; 36: 36–42.
46. Reus VI, Wolkowitz OM:
Antiglucocorticoid drugs in the treatment of
depression. Expert Opin. Investig. Drugs
2001; 10: 1789–1796.
47. Reus VI, Wolkowitz OM:
Antiglucocorticoid treatment of depression:
double-blind ketoconazole. Biol. Psychol.
1999; 45: 1070–1074.
48. Gaillard RC, Poffet D, Riondel AM,
Saurat JH: RU486 inhibits peripheral effects
of glucocorticoids in humans. J. Clin.
Endocrinol. Metab. 1985; 61: 1009–1011.
49. Jacobson PB, von Geldern TW, Ohman L,
Osterland M, Wang J, Zinker B, et al:
Hepatic glucocorticoid receptor antagonism
is sufficient to reduce elevated hepatic
glucose output and improve glucose control
in animal models of type 2 diabetes. J.
Pharmacol. Exp. Ther. 2005; 314: 191–200.
50. Stewart PM, Wallace AM, Atherden SM,
Shearing CH, Edwards CRW:
Mineralocorticoid activity of
carbenoxolone: contrasting effects of
carbenoxolone and liquorice on 11 beta
hydroxysteroid dehydrogenase activity in
man. Clin. Sci. 1990; 78(1): 49– 54.
51. Andrew R, Smith K, Jones GC, Walker
BR: Distinguishing the activities of 11 beta
hydroxysteroid dehydrogenases in vivo
using isotopically labeled cortisol. J. Clin.
Endocrinol. Metab. 2002; 87: 277–285.
52. Andrews RC, Rooyackers O, Walker BR:
Effects of the 11 beta hydroxysteroid
dehydrogenase inhibitor carbenoxolone on
insulin sensitivity in men with type 2
diabetes. J. Clin. Endocrinol. Metab. 2003;
88: 285–291.
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
94
53. Livingstone DE, Walker BR: Is 11 beta
hydroxysteroid dehydrogenase type 1 a
therapeutic target? Effects of
carbenoxolone in lean and obese Zucker
rats. J. Pharmacol. Exp. Ther. 2003; 305:
167–172.
54. Li RS, Nakagawa Y, Nakanishi T, Fujisawa
Y, Ohzeki T. Different responsiveness in
55. body weight and hepatic 11betahydroxysteroid
dehydrogenase (11beta-
HSD) type 1 mrna to 11beta-HSD inhibition
by glycyrrhetinic acid treatment in obese
and lean zucker rats. Metabolism 2004; 53:
600–606.
56. Barf T, Vallgarda J, Emond R, Häggström
C, Kurz G, Nygren A, et al:
Arylsulfonamidothiazoles as a new class of
potential antidiabetic drugs. Discovery of
potent and selective inhibitors of the 11
beta hydroxysteroid dehydrogenase type 1.
J. Med. Chem. 2002; 45: 3813–3815.
57. Xiang J, Ipek M, Suri V, Massefski W, Pan
N, Ge Y, et al: Synthesis and biological
evaluation of sulfonamidooxazoles and keto
sulfones: selective inhibitors of 11 betahydroxysteroid
dehydrogenase type 1.
Bioorg. Med. Chem. Lett. 2005; 15: 2865–
2869.
58. Hult M, Jornvall H, ppermann UCT:
Selective inhibition of human type 1 11bhydroxysteroid
dehydrogenase by synthetic
steroids and xenobiotics. Fed. Eur. Biochem.
Stud. 1998; 441: 25–28.
59. Alberts P, Engblom L, Edling N, Forsgren
M, Klingstrom G, Larsson C, et al: Selective
inhibition of 11betahydroxysteroid
dehydrogenase type 1 decreases blood
glucose concentrations in hyperglycaemic
mice. Diabetologia. 2002; 45(11): 1528–
1532.
60. Alberts P, Nilsson C, Selen G, Engblom
LO, Edling NH, Norling S, et al: Selective
inhibition of 11 beta hydroxysteroid
dehydrogenase type 1 improves hepatic
insulin sensitivity in hyperglycaemic mice
strains. Endocrinology 2003; 144: 4755–
4762.
61. Hermanowski-Vosatka A, Balkovec JM,
Cheng K, Chen HY, Hernandez M, Koo GC,
et al: 11 beta HSD1 inhibition ameliorates
metabolic syndrome and prevents
progression of atherosclerosis in mice. J.
Exp. Med. 2005; 202: 517–527.
62. Walker BR, Yau JL, Brett LP, Seckl JR,
Monder C, Williams BC, et al: 11 beta-
Hydroxysteroid dehydrogenase in vascular
smooth muscle and heart: implications for
cardiovascular responses to glucocorticoids.
Endocrinology 1991; 129: 3305–3312.
63. Hadoke PWF, Christy C, Kotelevtsev YV,
Brent CW, Christopher JK, Jonathan RS, et
al: Endothelial cell dysfunction in mice after
transgenic knockout of type 2, but not type
1, 11beta- hydroxysteroid dehydrogenase.
Circulation. 2001; 104(23): 2832–2837.
64. Small GR, Hadoke PW, Sharif I, Dover
AR, Armour D, Kenyon CJ, et al: Preventing
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
95
regeneration of glucocorticoids by 11 beta
hydroxysteroid dehydrogenase type 1
enhances angiogenesis. Proc. Natl. Acad.
Sci. USA 2005; 102: 12165–12170.
65. Thieringer R, Hermanowski-Vosatka A:
Inhibition of 11β-HSD1 as a novel treatment
for the metabolic syndrome: do
glucocorticoids play a role?. Exp. Rev.
Cardiovasc. Ther. 2005; 3(5): 911-924.
66. Wang MS, Shi H, Wang KS, Reidenberg
MM: Inhibition of 11β-hydroxysteroid
dehydrogenase in guinea pig kidney by
three bioflavonoids and their interactions
with gossypol. Acta Pharmacol. Sin. 2002;
23(1), 92-96.
67. Thieringer R, Le Grand CB, Carbin L, Cai
TQ, Wong B, Wright SD, et al: 11beta-
Hydroxysteroid dehydrogenase type 1 is
induced in human monocytes upon
differentiation tomacrophages. J. Immunol.
2001; 167: 30–35.
68. Walker BR, Yau JL, Brett LP, Seckl JR,
Monder C, Williams BC, et al: 11 beta
Hydroxysteroid dehydrogenasein vascular
smooth muscle and heart: implications for
cardiovascular responses to glucocorticoids.
Endocrinology 1991; 129: 3305–3312.
69. Hadoke PWF, Christy C, Kotelevtsev YV,
Williams BC, Kenyon CJ, Seckl JR, et al:
Endothelial cell dysfunction in mice after
transgenic knockout of type 2, but not type
1, 11 beta hydroxysteroid dehydrogenase.
Circulation 2001; 104(23):2832–2837.
70. Small GR, Hadoke PW, Sharif I, Dover
AR, Armour D, Kenyon CJ, et al: Preventing
regeneration of glucocorticoids by 11 beta
hydroxysteroid dehydrogenase type 1
enhances angiogenesis. Proc. Natl. Acad.
Sci. USA 2005; 102: 12165–12170.
71. Harris HJ, Kotelevtsev YV, Mullins JJ,
Seckl JR, Holmes MC: Intracellular
Regeneration of Glucocorticoids by 11β-
Hydroxysteroid Dehydrogenase (11β-HSD)-1
Plays a Key Role in Regulation of the
Hypothalamic-Pituitary-Adrenal Axis:
Analysis of 11β-HSD-1-Deficient Mice.
Endocrinology 2001; 142(1): 114–120.
72. Yau JL, Noble J, Kenyon CJ, Hibberd C,
Kotelevtsev Y, Mullins JJ, et al: Lack of tissue
glucocorticoid reactivation in 11 beta
hydroxysteroid dehydrogenase type 1
knockout mice ameliorates age-related
learning impairments. Proc. Natl. Acad. Sci.
USA 2001; 98(8): 4716–4721.
73. Sandeep TC, Yau JL, MacLullich AM,
Noble J, Deary IJ, Walker BR, et al: 11 beta
hydroxysteroid dehydrogenase inhibition
improves cognitive function in healthy
elderly men and type 2 diabetics. Proc. Natl.
Acad. Sci. USA 2004; 101: 6734–6739.
74. Stulnig TM, Oppermann U, Steffensen
KR, Schuster GU, Gustafsson JA: Diabetes
2002; 51(8): 2426-2433.
75. Cao G, Liang Y, Broderick CL, Oldham
BA, Beyer TP, Schmidt RJ, et al: Antidiabetic
Action of a Liver X Receptor Agonist
Mediated By Inhibition of Hepatic
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
96
Gluconeogenesis. J. Biol. Chem. 2003;
278(2): 1131-1136.
76. Laffitte BA , Chao LC, Li J, Walczak R,
Hummasti S, Joseph SB, et al: Activation of
liver X receptor improves glucose tolerance
through coordinate regulation of glucose
metabolism in liver and adipose tissue.
Proc. Natl. Acad. Sci. USA 2003; 100(9):
5419-5424.
77. Kurukulasuriya R, Link JT, Madar DJ, Pei
Z, Richards SJ, Rohde J , et al: Potential
drug targets and progress towards
pharmacologic inhibition of hepatic glucose
production. Curr. Med. Chem. 2003; 10(2):
123-153.
78. Link JT: Pharmacological regulation of
hepatic glucose production. Curr. Opin.
Investig. Drugs 2003; 4(4): 421-429.
79. Jacobson PB, von Geldern TW, Ohman L,
Osterland M, Wang J, Zinker B, et al:
Hepatic Glucocorticoid Receptor
Antagonism Is Sufficient to Reduce Elevated
Hepatic Glucose Output and Improve
Glucose Control in Animal Models of Type 2
Diabetes. J. Pharmacol. Exp. Ther. 2005;
314(1): 191-200.
80. Valsamakis G, Anwar A, Tomlinson JW,
Shackleton CH, McTernan PG, Chetty R, et
al: 11β-Hydroxysteroid Dehydrogenase
Type 1 Activity in Lean and Obese Males
with Type 2 Diabetes Mellitus. J. Clin.
Endocrinol. Metab. 2004; 89(9): 4755-4761.
81. Basu R, Singh RJ, Basu A, Chittilapilly EG,
Johnson CM, Toffolo G, et al: Splanchnic
cortisol production occurs in humans –
evidence for conversion of cortisone to
cortisol via the 11 beta hydroxysteroid
dehydrogenase type 1 pathway. Diabetes
2004; 53: 2051–2059.
82. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, T
Ohzeki et al: Leptin activation of
corticosterone production in hepatocytes
may contribute to the reversal of obesity
and hyperglycemia in leptin-deficient ob/ob
mice. Diabetes 2003; 52(6): 1409–1416.
83. Tomlinson JW, Moore JS, Clark PM,
Holder G, Shakespeare L, Stewart PM, et al:
Weight loss increases 11betahydroxysteroid
dehydrogenase type 1
expression in human adipose tissue. J. Clin.
Endocrinol. Metab. 2004; 89: 2711–2716.
84. Engeli S, Böhnke J, Feldpausch M,
Gorzelniak K, Heintze U, Janke J, et al:
Regulation of 11 beta hydroxysteroid
dehydrogenase genes in human adipose
tissue: influence of central obesity and
weight loss. Obes. Res. 2004; 12: 9–17.
85. De Kloet, Vreugdenhil ER: Stress in the
brain. Eur. J. Pharmacol.2000; 405(1-3):
187-198.
86. De Kloet, Vreugdenhil ER: Hormones
and the stressed brain. Ann. N.Y. Acad. Sci.
2004(1018): 1-15.
87. De Kloet, Vreugdenhil ER, Oitzl E, Joels
M: Brain Corticosteroid Receptor Balance in
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
97
Health and Disease. Endocr. Rev. 1998;
19(3): 269-301.
88. Moisan MP, Seckl JR: Edwards CR. 1lβ-
Hydroxysteroid Dehydrogenase Bioactivity
and Messenger RNA Expression in Rat
Forebrain: Localization in Hypothalamus,
Hippocampus, and Cortex. Endocrinology
1990; 127(3): 1450-1455.
89. Low SC, Moisan MP, Noble JM, Edwards
CR, Seckl JR: Glucocorticoids Regulate
Hippocampal 11β-Hydroxysteroid
Dehydrogenase Activity and Gene
Expression in vivo in the Rat. J.
Neuroendocrinol. 1994; 6(3): 285-290.
90. Rajan V, Edwards CR, Seckl JR: 11 beta-
Hydroxysteroid dehydrogenase in cultured
hippocampal cells reactivates inert 11-
dehydrocorticosterone, potentiating
neurotoxicity. J. Neurosci. 1996; 16(1): 65-
70.
91. Yau JL, Noble J, Kenyon CJ, Hibberd C,
Kotelevtsev Y, Mullins JJ, et al: Lack of
tissue glucocorticoid reactivation in 11β-
hydroxysteroid dehydrogenase type 1
knockout mice ameliorates age-related
learning impairments. Proc. Natl. Acad. Sci.
USA 2001; 98(8): 4716-4721.
92. Sandeep TC, Yau JL, MacLullich AM,
Noble J, Deary IJ, Walker BR, et al: 11β-
Hydroxysteroid dehydrogenase inhibition
improves cognitive function in healthy
elderly men and type 2 diabetics. Proc. Natl.
Acad. Sci. USA.2004; 101(17): 6734-6739.
93. de Quervain DJ, Poirier R, Wollmer MA,
Grimaldi LM, Tsolaki M, Streffer JR, et al:
Glucocorticoid-related genetic susceptibility
for Alzheimer's disease. Hum. Mol.
Genet.2004; 13(1): 47-52.
94. Rauz S, Walker EA, Shackleton CH,
Hewison M, Murray PI, Stewart PM:
Expression and Putative Role of 11β-
Hydroxysteroid Dehydrogenase Isozymes
within the Human Eye. Invest. Ophthalmol.
Vis. Sci.2001; 42(9): 2037-2042.
95. Rauz S, Cheung CM, Wood PJ, Coca-
Prados M, Walker EA, Murray P I, et al:
Inhibition of 11β-hydroxysteroid
dehydrogenase type 1 lowers intraocular
pressure in patients with ocular
hypertension. QJM 2003; 96(7): 481-490.
96. Barnes PJ, Adcock IM. How Do
Corticosteroids Work in Asthma? Ann.
Intern. Med. 2003; 139(5 Pt1): 359-370.
97. Barnes PJ, Adcock IM: Steroid resistance
in asthma. QJM 1995; 88(7): 455-468.
98. Wilckens T: Glucocorticoids and immune
function: physiological relevance and
pathogenic potential of hormonal
dysfunction. Trends Pharmacol. Sci. 1995;
16(6): 193-197.
99. Wilckens T, De Rijk R: Glucocorticoids
and immune function: unknown dimensions
and new frontiers. Immunol. Today 1997;
18(9): 418-424.
100. Munck A, Naray-Fejes-Toth A: The ups
and downs of glucocorticoid physiology
Research Article CODEN: IJPRNK ISSN: 2277-8713
Vijaykumar Arumugam, IJPRBS, 2013; Volume 2(5):78-99 IJPRBS
Available Online at www.ijprbs.com
98
Permissive and suppressive effects
revisited. Mol. Cell Endocrinol 1992; 90(1):
C1-4.
101. Zhou Z, Shackleton CH, Pahwa S,
White PC, Speiser PW: Prominent sex
steroid metabolism in human lymphocytes.
Mol. Cell Endocrinol. 1998; 138(1-2): 61-69.
102. Hennebold JD, Ryu SY, Mu HH,
Galbraith A, Daynes RA: 11 betahydroxysteroid
dehydrogenase modulation
of glucocorticoid activities in lymphoid
organs. Am. J. Physiol. 1996; 270(6 Pt 2):
R1296-1306.
103. Freeman L, Hewison M, Hughes SV,
Evans KN, Hardie D, Means TK, et al:
Expression of 11β-hydroxysteroid
dehydrogenase type 1 permits regulation of
glucocorticoid bioavailability by human
dendritic cells. Blood 2005; 106(6): 2042-
2049.
104. Teelucksingh S, Mackie AD, Burt D,
McIntyre MA, Brett L, Edwards CR:
Potentiation of hydrocortisone activity in
skin by glycyrrhetinic acid. Lancet 1990;
335(8697): 1060-1063.
105. Hennebold JD, Mu HH, Poynter ME,
Chen XP, Daynes RA: Active catabolism of
glucocorticoids by 11 beta-hydroxysteroid
dehydrogenase in vivo is a necessary
requirement for natural resistance to
infection with Listeria monocytogenes. Int.
Immunol. 1997; 9(1): 105-115.
106. Manelli F, Giustina A: Glucocorticoidinduced
osteoporosis. Trends. Endocrinol.
Metab. 2000; 11(3): 79-85.
107. Doga M, Bonadonna S, Burattin A,
Carpinteri R, Manelli F, Giustina A:
Bisphosphonates in the treatment of
glucocorticoid-induced osteoporosis. Front.
Horm. Res. 2002; 30: 150-164.
108. Cooper MS, Rabbitt EH, Goddard PE,
Bartlett WA, Hewison M, Stewart PM: 11β-
Hydroxysteroid Dehydrogenase Type 1
Activity Increases With Age and
Glucocorticoid Exposure. J. Bone Miner.
Res. 2002; 17(6): 979-986.
109. Cooper MS, Walker EA, Bland R, Fraser
WD, Hewison M, Stewart PM: Expression
and functional consequences of 11β-
hydroxysteroid dehydrogenase activity in
human bone. Bone 2000; 27(3): 375-381.
110. Cooper MS, Blumsohn A, Goddard PE,
Bartlett WA, Shackleton CH, Eastell R, et al:
11β-Hydroxysteroid Dehydrogenase Type 1
Activity Predicts the Effects of
Glucocorticoids on Bone. J. Clin. Endocrinol.
Metab. 2003; 88(8): 3874-3877.
111. Justesen J, Mosekilde L, Holmes M,
Stenderup K, Gasser J, Mullins JJ, et al: Mice
Deficient in 11β-Hydroxysteroid
Dehydrogenase Type 1 Lack Bone Marrow
Adipocytes, but Maintain Normal Bone
Formation. Endocrinology 2004; 145(4):
1916-1925.